SCHEMBL17809602

SCHEMBL17809602

CN1CCc2c1ccc(-c1cnn(C)c1)c2F

nearest known ligand 0.41

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 4/20 0.41
▸ CREBBP Q92793 4/20 0.41
▸ USP30 Q70CQ3 4/20 0.38
▸ ROCK2 O75116 1/20 0.38
▸ ROCK1 Q13464 1/20 0.38
▸ CDC42BPB Q9Y5S2 1/20 0.38
▸ ALOX5AP P20292 1/20 0.37
▸ FEN1 P39748 1/20 0.37
▸ AURKA O14965 1/20 0.35
▸ AURKB Q96GD4 1/20 0.35
▸ INCENP Q9NQS7 1/20 0.35
▸ TPX2 Q9ULW0 1/20 0.35
▸ BMPR1A P36894 1/20 0.35
▸ ACVRL1 P37023 1/20 0.35
▸ ACVR1 Q04771 1/20 0.35
▸ LRRK2 Q5S007 2/20 0.35
▸ PDK2 Q15119 1/20 0.34
▸ CLK2 P49760 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17809797 0.92 CREBBP (0.39) BRD4CREBBPROCK2ROCK1CDC42BPB
SCHEMBL17809615 0.84 BRD4 (0.38) BRD4CREBBPROCK2ROCK1CDC42BPB
SCHEMBL17806240 0.84 CREBBP (0.38) BRD4CREBBPUSP30ROCK2ROCK1
SCHEMBL17809532 0.80 GRM5 (0.39) BRD4CREBBPROCK2ROCK1CDC42BPB
SCHEMBL23055771 0.79 GRM5 (0.45) BRD4CREBBPAURKAAURKBINCENP
SCHEMBL17806246 0.79 CREBBP (0.37) BRD4CREBBPROCK2ROCK1CDC42BPB
SCHEMBL17785761 0.76 GPR119 (0.44) BRD4CREBBPUSP30LRRK2
SCHEMBL17785702 0.73 AURKA (0.40) BRD4CREBBPROCK2ROCK1CDC42BPB
SCHEMBL17809538 0.72 ERN1 (0.47) BRD4CREBBPUSP30AURKAAURKB
SCHEMBL17794805 0.72 BRD4 (0.43) BRD4CREBBPUSP30ROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3224258-B1 4,5,6,7-TETRAHYDRO-1H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS GENENTECH INC (US) 2019-08-14 — — EP disclosed
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2017-11-23 — — US disclosed
US-9763922-B2 Therapeutic compounds and uses thereof GENENTECH, INC. (US) 2017-09-19 — — US disclosed
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-06-09 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170333406-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 BRD4 11/4885CREBBP 6/4885USP30 2156/4885
US-20160158207-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF EP300, HDAC1, HDAC10 BRD4 11/4885CREBBP 6/4885USP30 2156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback